口服代谢性疾病药物的治疗学和新西兰药厂伙伴开发口服代谢性疾病药物,由OTR牵头研究,新西兰负责研制和销售。 OTR Therapeutics and Zealand Pharma partner to develop oral metabolic disease drugs, with OTR leading research and Zealand handling development and sales.

OTR治疗和新西兰制药公司结成了战略协作关系,发展代谢性疾病的口服小分子治疗,将OTR的药物发现平台与新西兰在肥胖症和代谢性健康方面的专长结合起来。 OTR Therapeutics and Zealand Pharma have formed a strategic collaboration to develop oral small-molecule treatments for metabolic diseases, combining OTR’s drug discovery platform with Zealand’s expertise in obesity and metabolic health. OTR将领导临床前研究,而新西兰则处理临床发展、监管档案和全球商业化。 OTR will lead preclinical research, while Zealand handles clinical development, regulatory filings, and global commercialization. OTR先头收到2 000万美元,可能增加到3 000万美元,并可能在与发展和销售挂钩的里程碑付款中赚取多达25亿美元,加上分层的一位数版使用费。 OTR receives $20 million upfront, potentially rising to $30 million, and could earn up to $2.5 billion in milestone payments tied to development and sales, plus tiered single-digit royalties. 该伙伴关系旨在扩大对患新陈代谢疾病的病人的治疗选择。 The partnership aims to expand treatment options for patients with metabolic conditions.